Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 4/20 | 0.39 |
| ▸ | RXRA | P19793 | 3/20 | 0.39 |
| ▸ | RXRG | P48443 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.34 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.34 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.34 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL214748 | 0.93 | RXRB (0.42) | RXRBRXRARXRGNPC1RAB9A | |
| SCHEMBL3144193 | 0.90 | RXRB (0.40) | RXRBRXRARXRGNPC1RAB9A | |
| SCHEMBL213985 | 0.86 | RXRB (0.45) | RXRBRXRARXRGNPC1RAB9A | |
| SCHEMBL213826 | 0.85 | RXRB (0.43) | RXRBRXRARXRGNPC1RAB9A | |
| SCHEMBL3148381 | 0.84 | RXRB (0.41) | RXRBRXRARXRGNPC1RAB9A | |
| SCHEMBL214666 | 0.84 | RXRB (0.43) | RXRBRXRARXRGNPC1RAB9A | |
| SCHEMBL212551 | 0.84 | RXRB (0.43) | RXRBRXRARXRGNPC1RAB9A | |
| SCHEMBL3144628 | 0.84 | RXRB (0.40) | RXRBRXRARXRGNPC1RAB9A | |
| SCHEMBL214324 | 0.83 | RXRB (0.42) | RXRBRXRARXRGNPC1RAB9A | |
| SCHEMBL213176 | 0.83 | RXRB (0.42) | RXRBRXRARXRGNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181187-B2 | Therapeutic agent for urinary excretion disorder | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| EP-2123273-B1 | THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER | ONO PHARMACEUTICAL CO (JP) | 2013-10-23 | — | — | EP | disclosed |
| US-20100076038-A1 | THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
| EP-2123273-A1 | THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER | ONO Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076038-A1 | THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER | PTGER1, TMPRSS15, EPDR1 | RXRB 4498/4885RXRA 4540/4885RXRG 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.